GridAI Technologies Corp.
Close on Oct 19, 2026
- Market cap
- $23.23T
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2018 Ended Sep 30, 2018 | Dec 20, 2018 | After market close | – | – | – |
Press releases
Announcements GridAI Technologies filed with the SEC
Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
100 Long Branch Avenue Unit
Material agreement · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Entero Therapeutics, Inc. Announces Corporate
Material agreement · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
(NASDAQ: ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand
Material agreement · Acquisition or disposition completed · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Entero Therapeutics, Inc. Announces Reverse
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC.
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Appoints Richard Paolone as CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling
Material agreement · Other events · EX-99.1 to Form 8-K
Entero Therapeutics Signs Letter of Intent to
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Entero Therapeutics’ Chairman and CEO
Regulation FD disclosure · EX-99.1 to Form 8-K
Wave BioPharma Changes Name to Entero Therapeutics
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
First Wave BioPharma, Inc. to raise approximately
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
First Wave BioPharma Announces Two Abstracts
Other events · EX-99.1 to Form 8-K
First Wave BioPharma Announces Completion of
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
First Wave BioPharma, Inc. to raise approximately
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
Other events · EX-99.1 to Form 8-K
Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical
Other events · EX-99.1 to Form 8-K
First Wave BioPharma Announces 1-for-20 Reverse
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Exclusive Global License Agreement for Capeserod from Sanofi
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
First Wave BioPharma, Inc. Announces Pricing
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation
Other events · EX-99.1 to Form 8-K
Wave BioPharma Regains Compliance With Nasdaq’s Minimum Bid Price Requirement
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
First Wave BioPharma Announces Results of Special
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
TO HOLDERS OF ITS COMMON
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
WAVE BIOPHARMA, INC. ANNOUNCES PRICING OF $6.0 MILLION PUBLIC OFFERING
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
First Wave BioPharma, Inc. Announces Closing
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
First Wave BioPharma, Inc. Announces Reverse
Listing notice · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders
Executive or director change · Other events · EX-99.1 to Form 8-K
First Wave BioPharma, Inc. Announces $9 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders
Regulation FD disclosure · EX-99.1 to Form 8-K
FIRST WAVE BIOPHARMA ANNOUNCES RESTRUCTURING OF MERGER CONSIDERATION PAYMENT TERMS WITH FORMER SHAREHOLDERS OF FIRST WAVE BIO
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K